UPB
NASDAQ · Biotechnology
Upstream Bio Inc
$6.31
-0.26 (-3.96%)
Open$6.58
Previous Close$6.57
Day High$6.69
Day Low$6.29
52W High$33.68
52W Low$5.85
Volume—
Avg Volume632.2K
Market Cap373.87M
P/E Ratio—
EPS$-2.90
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+291.1% upside
Current
$6.31
$6.31
Target
$24.68
$24.68
$18.50
$24.68 avg
$35.72
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 3.14M | 2.36M | 177.59M |
| Net Income | -157,817,354 | -106,761,589 | -3,219,143 |
| Profit Margin | -5,026.0% | -4,774.7% | -1.8% |
| EBITDA | -176,226,219 | -125,838,024 | -5,179,349 |
| Free Cash Flow | — | — | -3,332,995 |
| Rev Growth | +33.0% | +33.0% | -5.8% |
| Debt/Equity | — | — | 0.62 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |